drugset / Trial / NCT02068846
BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
Phase 3
Completed
17 enrolled
University of North Carolina, Chapel Hill
National Institute of Dental and Craniofacial Research (NIDCR) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to analyze BK viral infection in salivary gland diseases; specifically, to determine a definitive relationship between BK Virus and HIV associated salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1 to receive BK Virus antiviral (ciprofloxacin) or placebo for 28 days. Salivary function/protein secretion will be correlated with BK polyomavirus titers. It is expected that patients with HIV+SGD+ will have elevated oral BK polyomavirus viral loads and will benefit from Ciprofloxacin.
Timeline
- Start
- 2014-04
- Primary completion
- 2016-01
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ciprofloxacin | Small molecule | 500 mg | — |